Table 6 Potential predictors of MTX intolerance (MISS ≥ 6)

Male

0,70 (0,22; 2,22)

0,546

Age at onset (by 10 yrs)

1,61 (0,51; 5,02)

0,416

Age at MTX start (by 10 yrs)

1,46 (0,48; 4,47)

0,505

Interval from onset to MTX start (by 10 months)

0,41 (0,10; 1,58)

0,194

Uveitis before MTX treatment

0,87 (0,21; 3,67)

0,853

ANA positive

1,49 (0,51; 4,37)

0,465

Active joints (by 10 joints)

1,01 (0,55; 1,84)

0,979

Joints with limitation of motion (by10 joints)

1,12 (0,63; 1,98)

0,695

Physician global assessment of disease activity (by 10 mm)

1,22 (0,87; 1,69)

0,245

Parent/patient global assessment of well-being (by 10 mm)

0,88 (0,68; 1,14)

0,328

FW (by 10 mm/h)

1,26 (0,95; 1,67)

0,111

CRP (by 10 mg/l)

1,09 (0,89; 1,34)

0,409

CHAQ

0,30 (0,08; 1,17)

0,083

JADAS 71(á 10 points)

1,12 (0,68; 1,82)

0,659

Parenteral form of methotrexate

2,44 (0,56; 10,65)

0,236

Initial MTX dose (mg/m2)

1,15 (0,94; 1,40)

0,181

Polyarticular form of JIA

1,43 (0,36; 5,78)

0,612